Comparative Pharmacology
Head-to-head clinical analysis: PYQUVI versus TREXALL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYQUVI versus TREXALL.
PYQUVI vs TREXALL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, preventing the conversion of folic acid to tetrahydrofolate, thereby inhibiting DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and release of adenosine.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
Oral: 7.5-15 mg once weekly; subcutaneous: 7.5-15 mg once weekly for rheumatoid arthritis; may be increased up to 25-30 mg weekly based on response and tolerability.
None Documented
None Documented
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Terminal elimination half-life is 3-10 hours; for high-dose methotrexate, half-life is 8-15 hours. Clinically, monitoring at 24, 48, and 72 hours is standard to guide leucovorin rescue
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal elimination is minor (<10%)
Category C
Category C
Antimetabolite
Antimetabolite